Author

Barrett R. B. Nuttall

Observed names: B. Nuttall, Barrett Nuttall, Barrett R.B. Nuttall, Nuttall, Barrett

Institution: AstraZeneca (United States)

Observed institutions: University of Connecticut, AstraZeneca (United States)

ORCID: 0000-0002-0362-229X

Observed ORCID: 0000-0002-0362-229X

OpenAlex ID: A5014294375

Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance

2019 · Daniel Stetson, Ambar Ahmed, et al. · JCO Precision Oncology · 182

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

2022 · Eric Tu, Kelly McGlinchey, et al. · JCI Insight · 117

PDF

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

2023 · Mark Roschewski, Manish R. Patel, et al. · Clinical Cancer Research · 27

PDF

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET -Amplified Gastric Cancer

2020 · Melanie M. Frigault, Aleksandra Markovets, et al. · JCO Precision Oncology · 23

PDF

“Failure To Launch”: Development of a Reproductive Organ Linked to Symbiotic Bacteria

2023 · Sarah J. McAnulty, Allison H. Kerwin, et al. · mBio · 21

A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo

2023 · Burcu Bestas, Sandra Wimberger, et al. · Nature Communications · 18

PDF

Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma

2023 · Maria Secrier, Lara McGrath, et al. · Cancer Research Communications · 12

PDF

Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples

2025 · Barrett Nuttall, Daniel L. Karl, et al. · Clinical Epigenetics · 10

PDF

A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies

2021 · Graham P. Collins, Tracy N. Clevenger, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 9

PDF

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

2023 · Clare Sun, Raghuveer Mali, et al. · Blood · 8

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

2022 · Sven de Vos, Patrick M. Reagan, et al. · Blood · 5

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

2022 · Clare Sun, Melih Acar, et al. · Blood · 4

Abstract LB-249: Examination of analytical factors impacting concordance of plasma-tumor testing by next-generation sequencing (NGS)

2017 · Daniel Stetson, Brian Dougherty, et al. · Cancer Research · 4

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

2021 · Mark Roschewski, Veerendra Munugalavadla, et al. · Blood · 3

Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer

2026 · Valentina Cutano, Shanade Dunn, et al. · Molecular Cancer Therapeutics · 1

Abstract 1649: Large scale multi-omics concordance study of cyclin E1 identifies high expressing tumors lacking CCNE1 gene alterations across multiple tumor indications

2024 · Sophie E. Willis, Gemma N. Jones, et al. · Cancer Research · 1

Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing

2021 · Kathleen Burke, Barrett Nuttall, et al. · Blood · 1

Abstract LB-223: Examination of intra-assay variability in a commercial ctDNA NGS assay with triplicate clinical plasma and pooled normal samples

2018 · Daniel Stetson, Brian Dougherty, et al. · Cancer Research · 1

Supplementary Figure S4 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer